icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
Voir aussi
Décision d'accès précoce
22/12/2022
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
V1kcEv33Lpstte97